Product Datasheet

Aiolos/IKZF3 Antibody - BSA Free NBP2-24495

Unit Size: 0.1 mg

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

www.novusbio.com



technical@novusbio.com

Publications: 14

Protocols, Publications, Related Products, Reviews, Research Tools and Images at: www.novusbio.com/NBP2-24495

Updated 10/23/2024 v.20.1

Earn rewards for product reviews and publications.

Submit a publication at www.novusbio.com/publications Submit a review at www.novusbio.com/reviews/destination/NBP2-24495



NBP2-24495


Aiolos/IKZF3 Antibody - BSA Free

Alolos/INZF3 Altilbody - DSA Flee	
Product Information	
Unit Size	0.1 mg
Concentration	1.0 mg/ml
Storage	Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Clonality	Polyclonal
Preservative	0.02% Sodium Azide
Isotype	IgG
Purity	Immunogen affinity purified
Buffer	PBS
Product Description	
Host	Rabbit
Gene ID	22806
Gene Symbol	IKZF3
Species	Human, Primate
Reactivity Notes	Immunogen displays the following percentage of sequence identity for non-tested species: canine (88%), mouse (88%), rat (88%), equine (82%).
Immunogen	A portion of amino acids 350-400 of human IKZF3 was used as the immunogen.
Product Application Details	
Applications	Western Blot, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry
Recommended Dilutions	Western Blot 0.25 - 1.0 ug/mL, Immunohistochemistry reported in scientific literature (PMID 34207079), Immunocytochemistry/ Immunofluorescence 1:100




Images


Western Blot: Aiolos/IKZF3 Antibody [NBP2-24495] - Total protein from Jurkat cells and human tonsil was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/mL anti-IkZF3 in blocking buffer and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.



Immunocytochemistry/Immunofluorescence: Aiolos/IKZF3 Antibody [NBP2-24495] - IKZF3 antibody was tested in Jurkat cells at a 1:40 dilution against DyLight 488 (Green). Alpha tubulin and nuclei were counterstained against DyLight 568 (Red) and DAPI (Blue), respectively.



Western Blot: Aiolos/IKZF3 Antibody [NBP2-24495] - Analysis of IKZF3 in human spleen lysate in the 1) absence and 2) presence of immunizing peptide using this antibody at 0.25 ug/mL.



Publications

Jochem M, Schrempf A, Wagner LM et Al. Degradome analysis to identify direct protein substrates of small-molecule degraders Cell Chem Biol 2024-11-07 [PMID: 39536762]

Walker, Z J, Idler, B Et al. Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-Based Therapy. Clin Cancer Res 2021-02-01 [PMID: 33109736] (ICC/IF, Human)

Zou Y, Liu B, Li L Et al. IKZF3 deficiency potentiates chimeric antigen receptor T cells targeting solid tumors Cancer letters 2021-10-20 [PMID: 34687790] (WB)

Chen H, Liu J, Kaniskan HU Et al. Folate-Guided Protein Degradation by Immunomodulatory Imide Drug-Based Molecular Glues and Proteolysis Targeting Chimeras Journal of medicinal chemistry 2021-08-26 [PMID: 34378936]

Barankiewicz J, Szumera-Cieckiewicz A, Salomon-Perzynski A et al. The CRBN, CUL4A and DDB1 Expression Predicts the Response to Immunomodulatory Drugs and Survival of Multiple Myeloma Patients Journal of Clinical Medicine 2021-06-18 [PMID: 34207079] (IF/IHC, Human)

Wang Z, Zhou G, Risu N et al. Lenalidomide Enhances CAR-T Cell Activity Against Solid Tumor Cells Cell Transplant 2020-09-24 [PMID: 32967454] (WB, Human)

Liu J, Chen H, Ma L et al. Light-induced control of protein destruction by opto-PROTAC Sci Adv 2020-02-01 [PMID: 32128407] (WB, Human)

Kim E, Ten Hacken E, Sivina M, et al. The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment Leukemia 2019-12-20 [PMID: 31862959]

Zhu YX, Shi CX, Bruins LA et al. Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4 Blood Cancer J 2019-02-11 [PMID: 30741931] (WB, Human)

Costa F, Vescovini R, Bolzoni M et al. Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties Oncotarget 2017-08-08 [PMID: 28881793] (WB, Human)

Uehara T, Minoshima Y, Sagane K et al. Selective degradation of splicing factor CAPERalpha by anticancer sulfonamides. Nat. Chem. Biol. 2017-04-24 [PMID: 28437394]

Nguyen TV, Li J, Lu CJ et al. p97/VCP promotes degradation of CRBN substrate glutamine synthetase and neosubstrates. Proc. Natl. Acad. Sci. U.S.A. 2017-03-20 [PMID: 28320958] (WB, Human)

More publications at http://www.novusbio.com/NBP2-24495





Novus Biologicals USA

10730 E. Briarwood Avenue Centennial, CO 80112

USA

Phone: 303.730.1950 Toll Free: 1.888.506.6887

Fax: 303.730.1966

nb-customerservice@bio-techne.com

Bio-Techne Canada

21 Canmotor Ave Toronto, ON M8Z 4E6

Canada

Phone: 905.827.6400 Toll Free: 855.668.8722 Fax: 905.827.6402

canada.inquires@bio-techne.com

Bio-Techne Ltd

19 Barton Lane Abingdon Science Park Abingdon, OX14 3NB, United Kingdom Phone: (44) (0) 1235 529449

Free Phone: 0800 37 34 15 Fax: (44) (0) 1235 533420 info.EMEA@bio-techne.com

General Contact Information

www.novusbio.com

Technical Support: nb-technical@bio-

techne.com

Orders: nb-customerservice@bio-techne.com

General: novus@novusbio.com

Products Related to NBP2-24495

HAF008 Goat anti-Rabbit IgG Secondary Antibody [HRP]

NB7160 Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP]

NBP2-24891 Rabbit IgG Isotype Control

NBP1-89185PEP Aiolos/IKZF3 Recombinant Protein Antigen

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NBP2-24495

Earn gift cards/discounts by submitting a publication using this product: www.novusbio.com/publications

